Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

Rhea-AI Summary

Recro Pharma, Inc. (NASDAQ: REPH) announced the release of its fourth quarter and year-end financial results for 2021 on March 1, 2022, after market close. The company will hold a conference call at 4:30 p.m. ET to discuss these results and operational highlights. Recro specializes in contract development and manufacturing, focusing on small molecule therapeutics, with facilities in Gainesville, Georgia, and San Diego, California.

Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern

SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market close on Tuesday, March 1, 2022. Recro’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, March 1, 2022 to discuss the financial results and recent operational highlights.

To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S. at least ten minutes prior to the start time and reference conference ID 7549058. Those interested in listening to the conference call live via webcast may do so by visiting the “Events” page in the Investor section of the Company’s website, www.recrocdmo.com. In addition, an archived webcast will be available on the Company’s website approximately two hours after the event and will be available for 30 days.

About Recro
Recro (NASDAQ: REPH) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.

For more information about Recro’s CDMO solutions, visit recrocdmo.com.

FAQ

When will Recro Pharma release its Q4 2021 financial results?

Recro Pharma will release its Q4 2021 financial results on March 1, 2022, after market close.

What time is the Recro Pharma conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on March 1, 2022.

How can I access the Recro Pharma conference call?

To access the conference call, dial (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S. and reference conference ID 7549058.

Where can I find the archived Recro Pharma webcast?

The archived webcast will be available on Recro's website approximately two hours after the event and will remain available for 30 days.